Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206117127> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W4206117127 endingPage "TPS213" @default.
- W4206117127 startingPage "TPS213" @default.
- W4206117127 abstract "TPS213 Background: Regorafenib (R) is an oral multikinase inhibitor that blocks several protein kinases involved in angiogenesis and oncogenesis; it has a survival benefit in refractory metastatic colorectal cancer (mCRC). The current standard (std) treatment in patients (pts) with RAS wildtype (WT) mCRC is sequential treatment with an anti-EGFR antibody (AEA) followed by R. However, R, which is orally administered once daily, may be more convenient and thus preferable for pts than AEA. REVERCE, a Japanese trial, demonstrated a significant 5.8 month (mo.) survival benefit with regorafenib administered prior to AEA compared to the std sequence. Based off these findings, the proposed phase II trial is to confirm the observed survival benefit from regorafenib sequencing prior to anti-EGFR monoclonal antibody therapy in REVERCE in a US patient population. Methods: REVERCEII is an Academic and Community Cancer Research United (ACCRU) network-led randomized phase II study of R (dose escalation from 80mg to 160mg based on tolerance) prior to AEA (R+AEA) compared to standard sequencing (AEA+R) in pts with refractory RAS WT mCRC. Patients are randomized 1:1 to receive R (Arm A) vs. AEA (with or without irinotecan per investigator choice) (Arm B). At the time of disease progression or intolerance, patients will receive sequential treatment until disease progression. Eligibility criteria include histologically confirmed mCRC, ECOG ≤ 2, acceptable organ function, and patients must have had prior fluoropyrimidine, oxaliplatin and irinotecan, and no prior AEA nor R. The primary objective is to compare the overall survival (OS), the primary endpoint, between evaluable patients (eligible, consented, started protocol treatment) who were randomized to R+AEA (arm A) and AEA+R (arm B). With 83 OS events, we have 87% power to detect an improvement in median OS from 9 months to 14.5 mo., assuming 1-sided significance level of 0.15, and exponential distribution. The total sample size is 124 patients. Secondary endpoints include progression-free survival, objective response, and adverse events. The total study duration is expected to be 3 years. Clinical trial information: NCT04117945. Clinical trial information: 04117945." @default.
- W4206117127 created "2022-01-25" @default.
- W4206117127 creator A5005968330 @default.
- W4206117127 creator A5008464992 @default.
- W4206117127 creator A5017655519 @default.
- W4206117127 creator A5019091131 @default.
- W4206117127 creator A5033844346 @default.
- W4206117127 creator A5050740210 @default.
- W4206117127 creator A5051169402 @default.
- W4206117127 creator A5055915497 @default.
- W4206117127 creator A5064791048 @default.
- W4206117127 creator A5071706562 @default.
- W4206117127 creator A5073598889 @default.
- W4206117127 creator A5073917656 @default.
- W4206117127 creator A5074891676 @default.
- W4206117127 creator A5078543517 @default.
- W4206117127 date "2022-02-01" @default.
- W4206117127 modified "2023-09-26" @default.
- W4206117127 title "REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan." @default.
- W4206117127 doi "https://doi.org/10.1200/jco.2022.40.4_suppl.tps213" @default.
- W4206117127 hasPublicationYear "2022" @default.
- W4206117127 type Work @default.
- W4206117127 citedByCount "0" @default.
- W4206117127 crossrefType "journal-article" @default.
- W4206117127 hasAuthorship W4206117127A5005968330 @default.
- W4206117127 hasAuthorship W4206117127A5008464992 @default.
- W4206117127 hasAuthorship W4206117127A5017655519 @default.
- W4206117127 hasAuthorship W4206117127A5019091131 @default.
- W4206117127 hasAuthorship W4206117127A5033844346 @default.
- W4206117127 hasAuthorship W4206117127A5050740210 @default.
- W4206117127 hasAuthorship W4206117127A5051169402 @default.
- W4206117127 hasAuthorship W4206117127A5055915497 @default.
- W4206117127 hasAuthorship W4206117127A5064791048 @default.
- W4206117127 hasAuthorship W4206117127A5071706562 @default.
- W4206117127 hasAuthorship W4206117127A5073598889 @default.
- W4206117127 hasAuthorship W4206117127A5073917656 @default.
- W4206117127 hasAuthorship W4206117127A5074891676 @default.
- W4206117127 hasAuthorship W4206117127A5078543517 @default.
- W4206117127 hasConcept C121332964 @default.
- W4206117127 hasConcept C121608353 @default.
- W4206117127 hasConcept C126322002 @default.
- W4206117127 hasConcept C142424586 @default.
- W4206117127 hasConcept C143998085 @default.
- W4206117127 hasConcept C168563851 @default.
- W4206117127 hasConcept C203092338 @default.
- W4206117127 hasConcept C2776248978 @default.
- W4206117127 hasConcept C2776694085 @default.
- W4206117127 hasConcept C2779551604 @default.
- W4206117127 hasConcept C2780259306 @default.
- W4206117127 hasConcept C2780962732 @default.
- W4206117127 hasConcept C2908647359 @default.
- W4206117127 hasConcept C31760486 @default.
- W4206117127 hasConcept C526805850 @default.
- W4206117127 hasConcept C71924100 @default.
- W4206117127 hasConcept C87355193 @default.
- W4206117127 hasConcept C90924648 @default.
- W4206117127 hasConcept C99454951 @default.
- W4206117127 hasConceptScore W4206117127C121332964 @default.
- W4206117127 hasConceptScore W4206117127C121608353 @default.
- W4206117127 hasConceptScore W4206117127C126322002 @default.
- W4206117127 hasConceptScore W4206117127C142424586 @default.
- W4206117127 hasConceptScore W4206117127C143998085 @default.
- W4206117127 hasConceptScore W4206117127C168563851 @default.
- W4206117127 hasConceptScore W4206117127C203092338 @default.
- W4206117127 hasConceptScore W4206117127C2776248978 @default.
- W4206117127 hasConceptScore W4206117127C2776694085 @default.
- W4206117127 hasConceptScore W4206117127C2779551604 @default.
- W4206117127 hasConceptScore W4206117127C2780259306 @default.
- W4206117127 hasConceptScore W4206117127C2780962732 @default.
- W4206117127 hasConceptScore W4206117127C2908647359 @default.
- W4206117127 hasConceptScore W4206117127C31760486 @default.
- W4206117127 hasConceptScore W4206117127C526805850 @default.
- W4206117127 hasConceptScore W4206117127C71924100 @default.
- W4206117127 hasConceptScore W4206117127C87355193 @default.
- W4206117127 hasConceptScore W4206117127C90924648 @default.
- W4206117127 hasConceptScore W4206117127C99454951 @default.
- W4206117127 hasIssue "4_suppl" @default.
- W4206117127 hasLocation W42061171271 @default.
- W4206117127 hasOpenAccess W4206117127 @default.
- W4206117127 hasPrimaryLocation W42061171271 @default.
- W4206117127 hasRelatedWork W1838719144 @default.
- W4206117127 hasRelatedWork W1965063355 @default.
- W4206117127 hasRelatedWork W2037724349 @default.
- W4206117127 hasRelatedWork W2127366124 @default.
- W4206117127 hasRelatedWork W2224396711 @default.
- W4206117127 hasRelatedWork W2799282789 @default.
- W4206117127 hasRelatedWork W2808961664 @default.
- W4206117127 hasRelatedWork W2921589532 @default.
- W4206117127 hasRelatedWork W3003103377 @default.
- W4206117127 hasRelatedWork W3142077694 @default.
- W4206117127 hasVolume "40" @default.
- W4206117127 isParatext "false" @default.
- W4206117127 isRetracted "false" @default.
- W4206117127 workType "article" @default.